Also found in: Medical, Acronyms, Wikipedia.
Related to bupivacaine: lidocaine


A potent, long-acting anesthetic, C18H28N2, used for regional anesthesia in its hydrochloride form.

[bu(tyl) + pi(peridine) + (no)vacaine (popular rendering of the trademark Novocain, influenced by cocaine).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


(Medicine) a local anaesthetic of long duration, used for nerve blocks
[C20: perhaps from bu(tyl) + pi(pecoloxylidide), the drug's chemical components + -vacaine, from (No)vocaine]
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Mentioned in ?
References in periodicals archive ?
Alternate theories for the mechanism of action of ILE in bupivacaine toxicity have been suggested.
HTX-011 is a dual-acting, fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam.
To compare the effect of intraperitoneal hydrocortisone with intraperitoneal bupivacaine with regard to pain relief after laparoscopic cholecystectomy.
Twenty-one women were randomized to 0.5% bupivacaine, 5 mL injected into the cervix at the 3 o'clock position, and 5 mL injected into at the 9 o'clock position to a depth of 3 cm, after anesthesia induction but before insertion of the uterine manipulator.
The FDA had previously granted Breakthrough Therapy designation for HTX-011 based on the results of Phase 2 studies and two completed Phase 3 studies, which showed that HTX-011 produced significant reductions in both pain intensity and the need for opioids through 72 hours post-surgery compared to placebo and bupivacaine solution, the standard-of-care.
The completed clinical studies included two Phase 3 studies in which HTX-011 demonstrated superior, sustained postoperative pain relief for 72 hours and decreased the need for opioids, with more patients who were opioid-free compared to placebo and bupivacaine solution, the current standard-of-care, added the company.
After preloading with 10ml/kg of Ringers lactate, Group A received fixed dose of 10mg of 0.5% hyperbaric bupivacaine, while Group B received dose according to height and weight using Harten's dose chart.
Malavika Prabhu, M.D., from Massachusetts General Hospital in Boston, and colleagues evaluated whether a liposomal bupivacaine incisional block decreases postoperative pain after cesarean delivery.
Group I patients received 0.5% hyperbaric bupivacaine for spinal anesthesia and Group II patients received 0.75% hyperbaric bupivacaine for induction.